Pharma Pulse 8/22/24: Tufts Site Experience Survey, Obesity Could Be a Bonus for AZ & more

Tufts CSDD Site Experience Survey

The Tufts Center for the Study of Drug Development (Tufts CSDD) is conducting a study on investigative site perspectives and burden associated with Direct-to-Patient (DTP) shipment of study treatments and supplies.

Patients with IBD at a Greater Risk for Serious RSV

Researchers in a new study found that the overall risk of RSV-related hospitalization for adults with inflammatory bowel disease was greatest for those who were 18 to 49 years of age and those who were 65 years of age or older.

AstraZeneca Is a Cancer Leader. Obesity Could Be a Bonus.

AstraZeneca remains one of the best bets in Big Pharma, and potential success in obesity isn’t priced in to the stock.

OM1 Appoints Catherine Richards as President

OM1 announced the appointment of Catherine Richards, PhD, MPH, as its first President. Richards will oversee the Product, Engineering, Clinical Informatics, Client Services, Data Science, and Research teams. Her leadership will be pivotal in advancing OM1’s strategy, innovation, and collaboration to improve patient outcomes.

Natalie H. on LinkedIn

Pharmaceutical Executive thank you for including me in this issue!

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs